Malignant neoplasms of the lacrimal sac : Rarity among tear duct diseases.

19:03 EDT 30th March 2015 | BioPortfolio

Summary of "Malignant neoplasms of the lacrimal sac : Rarity among tear duct diseases."

Malignant neoplasms of the lacrimal sac are rare in the ophthalmic literature, for which there are only very limited diagnostic and therapeutic recommendations. We present five consecutive cases of our hospital from 2006 to 2009.
Retrospective analysis of all surgically treated patients with lacrimal duct diseases in the years 2006 to 2009, recording of malignant neoplasms and presentation of diagnostic and therapeutic approach.
From January 2006 until October 2009 we performed 213 dacryocystorhinostomies at the Eye Clinic, Charité Campus Virchow Klinikum. In five patients intrasaccal malignancies were histologically proven by biopsy. None of the patients showed typical symptoms such as bloody epiphora. In two patients, a squamous cell carcinoma was seen, and one patient showed an adenocarcinoma. The other patients had a lymphoma and a malignant fibrous histiocytoma. The therapeutic approach consisted of surgical resection and radiotherapy. Systemic manifestations did not occur in any of the five patients. In the limited follow-up period no recurrences and no metastases were seen.


Augenklinik, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Deutschland,

Journal Details

This article was published in the following journal.

Name: Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
ISSN: 1433-0423


PubMed Articles [10536 Associated PubMed Articles listed on BioPortfolio]

Lacrimal Duct Cyst Abscess.

Abstract Cystic dilatation within the lacrimal gland is thought to be related to chronic inflammation and scarring of the lacrimal gland ductules. We review the literature and discuss a case and of la...

Pancreatic Main-Duct Involvement in Branch-Duct IPMNs: An Underestimated Risk.

This study aimed to analyze a large single-center population of resected intraductal papillary mucinous neoplasms (IPMN) of the pancreas with respect to risk factors of malignant transformation.

Evaluation of the adhesive properties of the cornea by means of optical coherence tomography in patients with meibomian gland dysfunction and lacrimal tear deficiency.

The aim was to determine the influence of meibomian gland dysfunction (MGD) and aqueous tear deficiency dry eye (ADDE) on the adhesive properties of the central cornea by means of optical coherence to...

Anatomic study of the lacrimal fossa and lacrimal pathway for bypass surgery with autogenous tissue grafting.

Purpose: To study the microsurgical anatomy of the lacrimal drainage system and to provide anatomical evidence for transnasal endoscopic lacrimal drainage system bypass surgery by autogenous tissue gr...

The role of endoscopic ultrasound in the management of intraductal papillary mucinous neoplasms.

As the use of cross---sectional imaging increases so does the incidence of asymptomatic pancreatic cysts. Pancreatic neoplastic cysts can be broadly grouped into mucinous lesions and solid pseudopapil...

Clinical Trials [3131 Associated Clinical Trials listed on BioPortfolio]

Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time

The purpose of the study is to observe lacrimal fluid condition (tear film break-up time) chronologically after a single dose of AL-43546 ophthalmic products(0.15%, 0.25% and vehicle)a...

Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms

Pancreatic cysts are common, and some pancreas cysts have malignant potential. Usual treatment of these cysts is either observation or surgical removal of part or all of the pancreas. Mini...

Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction

This is a a prospective study of the WallFlex™ Biliary Partially-covered Stent designed to collect data to support regulatory clearance by the FDA in the United States and to determine t...

A Trial Comparing the Uncovered to the Covered Wallstent in the Palliation of Malignant Bile Duct Strictures

The purpose of the study is to determine the best management of bile duct narrowing (stricture) due to inoperable tumors. The bile duct is a tube that carries bile formed in the liver to t...

Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation

The objectives of this study are: - To compare the change in levels of tear proteins and inflammatory mediators pre and post administration between the intranasal and extranasal a...

Medical and Biotech [MESH] Definitions

The tear-forming and tear-conducting system which includes the lacrimal glands, eyelid margins, conjunctival sac, and the tear drainage system.

Interference with the secretion of tears by the lacrimal glands. Obstruction of the lacrimal sac or nasolacrimal duct causing acute or chronic inflammation of the lacrimal sac (DACRYOCYSTITIS). It is caused also in infants by failure of the nasolacrimal duct to open into the inferior meatus and occurs about the third week of life. In adults occlusion may occur spontaneously or after injury or nasal disease. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p250)

Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.

A tumor composed of spindle cells with a rich vascular network, which apparently arises from pericytes, cells of smooth muscle origin that lie around small vessels. Benign and malignant hemangiopericytomas exist, and the rarity of these lesions has led to considerable confusion in distinguishing between benign and malignant variants. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1364)

Diseases of the lacrimal apparatus.

Search BioPortfolio:

Relevant Topic

The top 5 most promising drugs (February 2014)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS LAUNCHED OR RECEIVING APPROVAL February 2014 Drug Disease Company Gazyva™ Chronic lymphocytic leukemia Biogen Idec/Genentech/ F. Hoffman-La Roche ...